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CYCLOSPORlr-; A, the new immunosuppressive 
agent developed by Borel and associates (2), 
should permit major advances in whole organ 
transplantation. When cyclosporin A was first 
used in patients by CaIne and co-workers (3, 5), 
it was hoped that no other drug would be routine-
ly required. Our dissenting opinion has been that 
cycJosporin A should be combined with steroid 
therapy from the outset (14-16). In this report, 
observations in 42 more recent instances of 
cadaveric renal transplantation will be used to 
examine that view. 
Cyclosporin A will be released soon for general 
use. When that time comes, physicians and sur-
geons who are unfamiliar with the combination 
thera py of cyclosporin A and steroids will need to 
have accurate foreknowledge of the convalescence 
patterns following renal transplantation and of 
how treatment with a standardized approach 
should be modified if recovery is unsatisfactory. 
The provision of such information is the second 
objective of this report. 
METHODS 
Case Material 
Forty-two patients had cadaveric renal trans-
plantation from two to eight months ago. Twen-
ty-two were receiving their first grafts and 20 
were undergoing transplantation for the second 
or third time. The recipients were consecutive 
and without exclusion, except for a woman from 
a previously reported series who under therapy 
with cyclosporin and steroids had previously lost 
a first kidney to primary hyperoxalosis (15). The 
primary hyperoxalosis could not be effectively 
treated because of pre-existing surgically pro-
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duced hypoparathyroidism. By compassionate 
agreement, cyclosporin A was continued for a 
second transplantation with the proviso that she 
not be considered part of a new study. The second 
graft was even more promptly ruined by primary 
hyperoxalosis than the first. 
Patient ages ranged from eight to 64 years, 
average 33.4±13.0, S.D. The primary recipients 
were deliberately transfused at least three times 
preoperatively, a preparatory step which was 
omitted for retransplantation. High risk medical 
factors, including diabetes mellitus, did not pre-
clude candidacy. 
HLA antigen matches at the A and B loci aver-
aged 1.3 of a possible 4.0. Only seven donors were 
matched with their recipients for 3 or 4 HLA an-
tigens, and at the other extreme, 15 had zero 
matches. Matching at the D locus was random, 
and there were no examples of complete D-relat-
ed locus compatibility. 
The serums of 13 of the 42 recipients contained 
antibodies against more than one-half of a 
lymphocyte panel contributed by 48 healthy do-
nors. Ten of the 13 patients with widely reacting 
antibodies were among the 20 undergoing re-
transplantation, "inacfverSe situation found only 
three times in the group of 22 recipients undergo-
ing primary transplantation. In seven of the 13 
patients, the preformed antibodies were warm 
anti-T lymphocyte cytotoxins which reacted 
against more than 90 per cent of the lymphocyte 
panel. 
In four of the latter seven instances, the 
recipient serums that had been collected and 
stored as recently as three weeks earlier complete-
ly killed the lymphocytes of the actual donor, al-
though cross matches were negative with serums 
drawn on the day of operation. In most centers, 
this finding is construed as a positive cross match 
and precludes transplantation. 
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FIG. 1. Benign convalescence under cyclosporin A, CyA, steroid therapy, Class 1. 
Cr, Serum creatinine. 
Postoperative Diagnostic Studies 
A noninvasive and noninstrumental approach 
to management was taken. Simple measures were 
the most important, including routine determina-
tions of blood urea nitrogen and serum creatinine. 
Close attention to urinary output often allowed 
the diagnosis of rejection to be made before the re-
sults of blood chemistry analyses became avail-
able. Because wound tenderness, graft swelling 
and fever were common during rejection (16), 
the patients were examined at least once a day by 
experienced observers. 
A day or two after transplantation, the grafts 
were studied with ultrasound to be sure that ure-
teral obstruction or perinephric fluid collection 
was not present. A radionuclide scan of the new 
kidney was obtained as a base line in the event 
that later differentiation of rejection from cyclo-
sporin A nephrotoxicity might become necessary. 
Stables and colleagues (13) have shown that 
severely retarded renal blood flow in a poorly 
functioning graft is most characteristic of rejec-
tion, and we (10, 16) have shown that a normal 
or nearly normal renal flow scan with reduced 
excretion is most compatible with a differential 
diagnosis between cyclosporin A nephrotoxicity 
and nonspecific acute tubular necrosis. 
Adjustment of drug dosages was a supremely 
important diagnostic tool. If manipulation of the 
steroid and cyclosporin A did not restore failing 
graft function, instrumentation was undertaken 
in six of the 42 recipients, including five, two and 
two examples each of renal biopsy, angiography 
and retrograde catheterization. 
Monitoring of the immunologic status of the 
recipients and measurement of plasma concentra-
tions of cyclosporin A were frequently carried 
out, but the results had no influence on day to day 
management and will not be reported herein. 
Classification oj ConvaLescence 
Recovery of recipients who achieved prompt, 
sustained and satisfactory graft function was 
termed Class 1. If an initial diuresis, however 
brief, was followed by a secondary decline of 
renal function, the course was designated Class 2. 
The period of initial diuresis sometimes lasted for 
less than six hours before shut down ensued. In a 
Class 3 convalescence, anuria was present at the 
outset. 
Convalescence Classification and Immunosuppres-
sive Therapy 
Treatment with cyclosporin A was given as 
previously recommended (14, 15), beginning 
with an initial oral dose of 17.5 milligrams per 
kilogram four to six hours before operation (Fig. 
1). Twenty-four hours postoperatively, the same 
dosage was given by mouth. Intramuscular or in-
travenous administration was not necessary since 
all of the patients were able to resume a diet 
promptly. Thereafter, the daily dose of 17.5 mil-
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FIG. 2. Class 2 recovery, with secondary deterioration of graft func-
tion which was immediately responsive to increased steroid therapy. 
The clinical diagnosis was rejection. 
Ii grams per kilogram was divided, half being 
given every 12 hours. If there was no subsequent 
reason for change, the same daily drug dosages 
were continued for at least two months. 
Steroid therapy in adults was begun just before 
or during operation with an intravenous bolus of 
1 gram methyl prednisolone. Afterward, the 
adult patients were given a five day course of 
prednisone, beginning with 200 milligrams the 
first day in six hourly divided intravenously ad-
ministered doses. With subsequent daily reduc-
tions of 40 milligrams, the daily oral amount of 
prednisone had reached 40 milligrams by the fifth 
postoperative day. On the sixth day, the daily 
dose was reduced to a maintenance level of 20 
milligrams from which further weaning was 
gradual (Fig. 1). The same steroid schedule was 
used for all adults without consideration of body 
weight, but for children, the peak and mainte-
nance dosages were set lower (Fig. 2) . 
CLass 7 recovery. This standardized therapeutic 
regimen was followed when early recovery was 
uncomplicated (Fig. 1). 
Class 2 recovery. If an initial diuresis was fol-
lowed by a secondary decline of renal function, 
rejection was assumed to be present. Urgent 
treatment was given intravenously with 1 gram of 
hydrocortisone. The same five day burst of pred-
nisone that had been used at the outset was 
repeated (Figs. 2 and 3), but the step-down of 
prednisone dosage was sometimes stopped at 30 
milligrams per day. Local homograft irradiation 
with 450 rads at depth was often begun in three 
doses of 150 rads every other day (Figs. 2 and 3). 
Some of the patients were treated with low dos-
ages of heparin as was also irregularly done in 
patients with Class 1 and Class 3 courses. 
Some of the patients who had renal function 
for only a few hours before the grafts shut down 
were just at the beginning of the initial burst ther-
apy with prednisone. In this minority of Class 2 
recipients, the original steroid schedule was not 
altered for several days, after which time a second 
steroid burst was considered if improvement had 
not occurred. 
Whether secondary graft deterioration was very 
early or later, nephrotoxicity of cyclosporin A 
was kept in mind. This diagnosis became more 
likely if prompt and complete reversal was not 
obtained by the steroid increments already given 
and especially if repeat scans now showed main-
tenance of good renal blood flow. The daily doses 
of cyclosporin A were dropped to 10 milligrams 
per kilogram or occasionally lower (Fig. 3). 
Maintenance prednisone doses in adults were not 
kept above 30 milligrams per day, and usually, 
they were 20 milligrams. 
For patients who did not respond, bolus ther-
apy with 1 gram of intravenously given hydrocor-
tisone was added every four or five days (Fig. 3) . 
With the relatively low maintenance dosages of 
prednisone, the patients were not ill during the 
time they were placed back on dialysis while 
waiting recovery. 
Class 3 recovery. For patients who had im-
mediate anuria postoperatively, the standardized 
immunosuppressive therapy was given (Fig. 4) 
with the assumption that the diagnosis was non-
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FIG. 3. Class 2 recovery which was not promptly responsive to steroid therapy, 
prompting a reduction in the dosage of cyclosporin A. The angiogram showed a pa-
tent arterial system with a stripped tree appearance of the distal vessels. The biopsy 
showed glomerulitis. Although oliguria was prolonged, the eventual result was 
good. 
specific acute tubular necrosis. If recovery had not 
occurred within ten to 14 days, drug manipula-
tion would have been instituted as for Class 2 pa-
tients, but this was not necessary since recovery 
occurred spontaneously. 
RESULTS 
Mortality and Morbidity 
None of the 42 recipients has died. Life-threat-
ening infections were not seen, although annoy-
ing virus infections were frequent, most common-
ly caused by herpes simplex. One patient was 
treated for a mild Pneumocystis carinii pneumo-
nitis, and another had a wound abscess after 
homograft nephrectomy. 
An 18 year old man had a perforation of the 
ileum six months after transplantation. The re-
TABLE I.-CLASSIFICATION OF EARLY RECOVERY 
AFTER 40 CADAVERIC TRANSPLANTATIONS 
Features 
Class 1. uneventful recovery ..... . 
Class 2, secondary deterioration of 
early function ............... . 
Class 3. anuria at outset ........ . 
Follow-up is two to eight months. 
No. 
13 (32.5) 
24" (60) 
3 (7.5) 
Good outcome 
13/13 
22/24 
3/3 
'Six of these patients had an initial diuresis which began to shut down 
within a few hours_ They would have been excluded from cyclosporin therapy 
if six or 12 hour urine output of 50 milliliters per hour were required as 
originally recommended for inclusion by Caine and others (3, 5). 
N umbers in parentheses signify percentages. 
sected specimen contained two discrete masses 
which were called lymphomas by conventional 
histopathologic criteria. The daily cyclosporin A 
dose was reduced from 17.5 to 9.0 milligrams per 
kilogram with a maintenance prednisone dose of 
15 milligrams per day. He has not had further 
difficulties in the ensuing four months. The re-
sults of special studies of the tumors demonstrated 
Epstein-Barr nuclear antigen in the B lymphoid 
cells. Further studies are in progress to character-
ize the lymphoid tissue which was similar to that 
in another patient who was eventually diagnosed 
as having a polyclonal lymphoproliferative reac-
tion (15). 
Graft Losses 
Primary transplantation. Twenty-one or 95.5 
per cent of the 22 primary grafts are functioning. 
One kidney was lost promptly when, after an 
ABO blood group typing error, an A kidney was 
transplanted into an 0 recipient in violation of 
well accepted compatibility guidelines. 
Retransplantation. Seventeen or 85 per cent of 
the 20 kidneys used for retransplantation are 
functioning. One graft was lost within 48 hours 
from a technical error and thrombosis of the renal 
artery. Two other grafts were rejected and 
removed after three and 11 weeks. 
-------'-------
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Incidence of Convalescent Classes 
Excluding the two patients in whom trans-
plantations were flawed by ABO ~yping or tech-
nical surgical errors, 40 were available for clas-
sification (Table I).' Only about one-third of 
these 40 recipients had the completely uneventful 
recovery of Class 1, whereas the other two-thirds 
had either secondary deterioration of initial func-
tion, Class 2, or the immediate anuria of Class 3 
(Table I) . 
The incidence of the convalescence classes was 
different after primary grafting versus retrans-
plantation (Table II). Twice as many primary 
transplant recipients had the benign recovery of 
those in Class 1 as was observed in the immuno-
logically more difficult patients undergoing re-
transplantation (Table II). Three-quarters of 
the recipients of second or third grafts had second-
ary deterioration of renal function from whatever 
level was initially observed. Commonly, this de-
terioration was very early, even within four to six 
hours. 
There were only three patients with the im-
mediate anuria of Class 3 (Tables I and II). 
These recipients recovered in the usual way after 
an acute tubular necrosis and were managed 
thereafter in the same way as Class 1 patients. 
Renal Function 
Difficulties in the early postoperative period 
tended to be transient and usually did not effect 
the ultimate renal function. All but four of the 38 
recipients still bearing grafts have serum creati-
nine concentrations of less than 3 milligrams per 
cent. The other four have stable values of 3.0 to 
3.5 milligrams per cent. The average creatinine 
level for the entire group is 2.0±O.7, S.D., milli-
grams per cent. 
Incidence of Postoperative Dialysis 
Of the total group of 42 patients, four or 9.5 
per cent were returned to chronic dialysis and the 
transplants were removed. Two of the four grafts 
were lost because of the ABO typing or surgical 
technical errors already cited, and the two others 
were rejected. Fifteen of the 38 patients who 
eventually recovered required one to ten dialysis 
in the early postoperative period. The two pa-
tients who had kidney rejection were maintained 
on dialysis for three and 11 weeks before giving 
up. 
DISCUSSION 
The safety and efficacy of combination therapy 
with cyclosporin A and steroids were noted before 
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FIG. 4. Class 3 convalescence with immediate anuria. 
The graft was from a 13 year old donor and had warm is-
chemia for an unknown time, estimated 20 to 60 minutes, 
before cooling. Therapy with cyclosporin A and prednisone 
was by the standard schedule. 
( 14-16) and confirmed in the more recent expe-
rience with 42 patients recorded herein. None of 
these patients has died. Ninety-six per cent of the 
primary grafts are functioning, as well as 85 per 
cent of the organs used for retransplantation. 
Although the follow-up periods are short, longer 
follow-up studies of our earlier series (15) and 
that of CaIne and co-authors (4) have not 
revealed a tendency for patients under cyclospo-
rin A to have later catch-up graft losses or to have 
major delayed morbidity from other causes. We 
and Caine and others (4) have not had the disil-
I usionment reported by Carpenter (6) and 
Sweny (17) and their associates in their first 
trials with cyclosporin A. 
As new teams begin using cyclosporin A, it 
will be important to avoid the unrealistic expecta-
tions about early convalescence that could be en-
gendered by the high long term success rates 
TABLE II,-INCIDENCE OF CONVALESCENCE 
CLASSES AFTER PRIMARY GRAFTING AND RE-
TRANSPLANTATION 
Class 7, 
sustamed 
functIOn 
21 Primary grafts. 9 (42.8) 
19 Retransplants. . 4 (21 ) 
Class 2, 
secondary graft 
deterioratIOn 
10 (47.6) 
14(73.7) 
N umbers in parentheses are percentage. 
Class 3. 
immediate 
anurza 
2 (9,6) 
1 (5.3) 
.. _-_ .. _---_._-_. 
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which alreadv have been achieved by CaIne and 
co-workers (4) and by us (15). Of the 42 recent-
ly treated patients reported herein, only a third 
had a completely uneventful recovery. More than 
40 per cent required some support with dialysis 
in the early postoperative period, because of 
either immediate anuria or secondary deteriora-
tion of initial graft function. The exceptionally 
high incidence of early renal failure after retrans-
plantation was evidence for major adverse im-
munologic factors in these troublesome, but even-
tual! y manageable, patients whom Ascher and 
colleagues (1) have shown to be at high risk 
under conventional immunosuppression from 
both rejection and lethal complications. 
The two principal factors which have influ-
enced the convalescence of our previously (15, 
16) and more recently treated patients have been 
rejection ;and nephrotoxicity from cyclosporin A. 
We (1 5. 16) and Carpenter and co-authors (6) 
have reported an extremely high incidence of 
c1inicallv cliagnosed or biopsy proved rejection. 
Control of the rejections with steroid therapy has 
been surprisingly easy (16), even in patients un-
dergoing retransplantation. The nephrotoxicity 
first noted by CaIne (3) and Powles (11) and 
their colle.ligues has been confirmed and charac-
terized in our patients (9,16). 
The therapeutic regimen which we are recom-
mending was designed to minimize diagnostic 
confusion between these two factors without re-
sorting to routine biopsy or other instrumenta-
tion, to prevent permanent damage to the new 
kidney, to avoid jeopardizing the patient with 
over immunosuppression and to achieve these 
ends without the kinds of sophisticated immuno-
logic and pharmacologic monitoring which is 
available in only a few centers. The last objective 
which we were able to achieve will be an impor-
tant determinant in making cyclosporin A valu-
able for eventual widespread clinical use. 
The use of cyclosporin A and steroids has had 
analogies to conventional combined therapy with 
azathioprine and prednisone but with greater 
efficiency in the control of rejection at much lower 
average steroid dosages. The conservative use of 
steroids with cyclosporin A from the time of 
transpbntation has allowed protection of even-
tual graft function and has allowed stepwise ad-
justments of both agents to be a keen diagnostic 
tool with the main criterion of differential diag-
nosis between rejection and nephrotoxicity being 
the therapeutic response to change. However, 
effective treatment has not depended upon early 
graft function. Many of the patients in this series 
did not have the mlOlmum early postoperative 
diuresis which CaIne and associates (3, 5) have 
recommended as a condition for therapy with cy-
closporin A. Although the luxury was lost of cor-
relating graded drug changes with therapeutic re-
sponse, these recipients were effectively treated 
without the use of the immunologic or phar-
macologic monitoring techniques advocated by 
Keown (8), Rynasiewicz (12) and Kahan, (7) 
and their co-authors. 
It is possible, but unlikely, that monitoring 
techniques eventually will delineate exactly the 
cause of renal graft dysfunction in the early post-
operative period or later. In this series, the rapid 
and sometimes simultaneous drug adjustments in 
Class 2 and 3 patients accommodated both of the 
possibilities of rejection and cyclosporin A neph-
rotoxicity. Often, a final precise differential diag-
nosis could not be made even in retrospect. It was 
never assumed that postoperative renal dysfunc-
tion was attributable solely to rejection or neph-
rotoxicity of cyclosporin A. The guiding assump-
tion was that both factors could and probably did 
contribute. Thus, the eventual therapeutic adjust-
ment in patients with persistent renal dysfunction 
often was to increase the dosages of steroids and 
temporarily to reduce the dosages of cyclosporin A. 
SUMMARY 
The postoperative convalescence period was 
analyzed for 42 consecutive patients who had 
cadaveric renal transplantation under therapy 
with cyclosporin A and steroids. Twenty-two of 
the patients underwent transplantation for the 
first time, and the other 20 had retransplantation. 
None of the recipients has died. With follow-up 
period of two to eight months, the survival rate of 
grafts is 96 per cent after first transplantation and 
85 per cent after retransplantation. Immuno-
suppression with a standard regimen was used 
for all patients at the outset. Early convalescence 
was highly variable, often necessitating adjust-
ments of cyclosporin A and steroid dosage to ac-
commodate the possibilities of rejection or cyclo-
sporin A nephrotoxicity, or both, simultaneously. 
Management problems were more frequent and 
complex in patients undergoing retransplanta-
tion. From the results, a classification of convales-
cence patterns was evolved, with recommenda-
tions about how standardized initial therapy 
should be adjusted if the renal graft does not func-
tion promptly or deteriorates later. 
REFERENCES 
1. ASCHER, N. L., AHRENHOLZ, D. H .. SIMMONS, R. L., 
and others. 100 second renal allografts from a single 
Starzl et al.: CONVALESCENCE AND THERAPY AFTER RENAL TRANSPLANTATION 7 
transplantation institution. Transplantation, 1979, 27: 
30. 
2. BOREL, J. F., FEURER, C., GUBLER, H. U., and others. 
Biological effects of cyclosporin A; a new antilymphocy-
tic agent. Agents Actions, 1976, 6: 468. 
3. CADlE, R. Y., ROLLES, K., WHITE, D. J. G., and others. 
Cyclosporin A initially as the only immunosuppressant 
in 34 recipients of cadaveric organs; 32 kidneys, 2 pan-
creases, and 2 livers. Lancet, 1979, 2: 1033. 
4. CALNE, R. Y., WHITE, D. J. G., EVANS, D. B., and 
others. Cyclosporin A in cadaveric organ transplanta-
tion. Br. Med. J., 1981; 282: 934. 
5. CALNE, R. Y., WHITE, D. J. G. THlRU, S., and others. 
Cyclosporin A in patients receiving renal allografts 
from cadaver donors. Lancet, 1978, 2: 1323. 
6. CARPENTER, B. J., TILNEY. N. L., STROM, T. B., and 
others. Cyclosporin A in cadaver renal allografts. Kid-
ney Int., 1981; 19: 265. 
7. KAHAN, B. D., V AN BUREN, C. T., LIN, S. N., and 
others. Immunopharmacologic monitoring of cyclospo-
rin A treated recipients of cadaveric kidney allografts. 
Transplantation, in press. 
8. KEOWN, P. A., STILLER, C. R., ULAN, R. A., and others. 
Immunological and pharmacological monitoring in the 
clinical use of cyclosporin A. Lancet, 1981, 1: 686. 
9. hifkq~1AiMI G. B. G., IWATSUKI, S., and STARZL, T. E. 
:'-oiephrotoxicity of cyclosporin A in liver and kidney 
transplant patients. Lancet, 1981, I: 470. 
10. KUNn1ALM, G. B. G., KLINGENSMITH, W. C., IWAT-
SUKl"S., .and ?th~rsK TC-99m-DTPA and I-13I-hippu-
ran findmgs m liver transplant recipients treated with 
cyclosporin A. Radiology, in press. 
II. POWLES, R. J., CLINK, H. M., and SPENCE, D. Cyclos-
porin A to prevent graft-versus-host disease in man 
after allogenic bone-marrow transplantation. Lancet, 
1980,1: 327. 
12. RYNASIEWICZ, J. J., SUTHERLAND, D. E. R., SIMMONS, 
R. L., and others. Cyclosporin A for the oliguric renal 
transplantation patient. Lancet, 1981, 1: 276. 
13. STABLES, D. P., KLINGENSMITH III, C. W., and 
JOHNSON, M. L. Renal transplantation. Diagnostic 
imaging in renal disease, 1979, 9: 167. 
14. STARZL, T. E., IWATsuKI, S., KLINTMALM, G. B. G., and 
others. Liver transplantation, 1980, with particular 
reference to cyclosporin A. Transplant Proc., 1981, 13: 
281. 
15. STARZL, T. E., KUNTMALM, G. B. G., IWATSUKI, S., and 
others. Cyclosporin A and steroid therapy in 66 cadaver 
kidney recipients. Surg. Gyneco!. Obstet., 1981, 153: 
486. 
16. STARZL, T. E., WElL III, R. IWATSUKI, S., and others. 
The use of cyclosporin A and prednisone in cadaver kid-
ney transplantation. Surg. Gyneco!. Obstet., 1980, 151: 
17. 
17. SWENY, P., FARRINGTON, K., YOUNIS, F., and others. 
Sixteen months experience with cyclosporin r\ in 
human kidney transplantation. Transplant Proc., 1981, 
13: 365. 
